Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: Applying matching-adjusted indirect comparison methodology

CNS Drugs

Volumn 27, Issue 11, 2013, Pages 943-953

  Sikirica, Vanja ^a   Findling, Robert L ^b   Signorovitch, James ^c   Erder, M Haim ^a   Dammerman, Ryan ^a   Hodgkins, Paul ^a   Lu, Mei ^c   Xie, Jipan ^c   Wu, Eric Q ^c  

^a SHIRE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; GUANFACINE; PLACEBO;

ADOLESCENT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; PLACEBO EFFECT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COMPARATIVE EFFECTIVENESS RESEARCH; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANFACINE; HUMANS; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84887063737     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0102-x     Document Type: Article

References (23)

1. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. Diagnostic and statistical manual of mental disorders, 4th ed, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000, p. 85-93.
2. Wolraich M, Brown L, Brown RT, et al. Implementing the key action statements: an algorithm and explanation for process of care for the evaluation, diagnosis, treatment, and monitoring of ADHD in children and adolescents. Pediatrics. 2011;128(5, supplemental information):SI1-21.
3. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2009;9(3):573-603 (viii).
4. ® (atomoxetine hydrochloride) capsules for oral use [package insert]. Indianapolis: Eli Lilly and Company; 2011.
5. ® (guanfacine) extended-release tablets [package insert]. Wayne: Shire Pharmaceuticals LLC. 2013.
6. Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role. 2007; 1-35.
7. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 2011;14(4):417-28.
8. Ali R, Hanger M, Carino T. Comparative effectiveness research in the United States: a catalyst for innovation. Am Health Drug Benefits. 2011;4(2):68-72.
9. Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940-7.
10. Piantadosi S, Byar DP, Green SB. The ecological fallacy. Am J Epidemiol. 1988;127(5):893-904.
11. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935-45.
12. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.
13. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.
14. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-8.
15. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
16. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-901.
17. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-7.
18. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton: CRC Press; 1993.
19. Report to the President and the Congress on Comparative Effectiveness Research. http://www.hhs.gov/recovery/programs/cer/execsummary.html. Accessed 7 August 2012.
20. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med. 2010;2(37):37cm18.
21. Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14(4):186-201.
22. Goodman D, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Prim Psychiatry. 2010;17(3):44-52.
23. Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila). 2009;48(7):723-33.